Beta Synuclein Protein

Active Human Recombinant Beta Synuclein Protein Monomer Catalog No. SPR-405



Discovery through partnership | Excellence through quality

Product Name

EAGLE BIOSCIENCES, INC.
20A NW BLVD, SUITE 112 NASHUA, NH 03063
P: 617-419-2019 F: 617-419-1110
WWW.EAGLEBIO.COM — INFO@EAGLEBIO.COM



Beta Synuclein Protein

Description
Active Human Recombinant Beta Synuclein Protein Monomer
Applications
WB, SDS-PAGE, In vivo assay, In vitro assay
Concentration
Lot/batch specific. See included datasheet.
Conjugates
No tag
Nature
Recombinant
Species
Human
Expression System
E. coli
Purity
>95%
Protein Length
Full Length
Field Of Use
Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.

Properties

Storage Buffer

PBS pH 7.4

Storage Temperature

-80°C

Shipping Temperature

Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order.

Purification

Ion-exchange Purified

Specificity

14.28 kDa

Cite This Product

Human Recombinant Beta Synuclein Protein (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog #SPR-405)

Certificate Of Analysis

Certified >95% pure using SDS-PAGE analysis.

Biological Description

Alternative Names

14 kDa brain-specific protein, Beta-synuclein Protein, Phosphoneuroprotein 14 Protein, PNP14 Protein, Sncb Protein, Synuclein beta Protein, SYUB_HUMAN Protein

Research Areas

Alzheimer's Disease, Neurodegeneration, Neuroscience, Parkinson's Disease, Synuclein, Tangles & Tau

Cellular Localization

Cytoplasm

Accession Number	
NP_001001502.1	
Gene ID	
6620	
Swiss Prot	
Q16143	

Scientific Background

Alzheimer's Disease (AD) is the most common neurodegenerative disease, affecting 10% of seniors over the age of 65 (1). It was named after Alois Alzheimer, a German scientist who discovered tangled bundles of fibrils where neurons had once been in the brain of a deceased patient in 1907 (2). Beta synuclein is abundant in neurofibrillary lesions of patients with Alzheimer's Disease. Beta synuclein is suggested to be an inhibitor of alpha synuclein aggregation- protecting the central nervous system from the neurotoxin effects of alpha synuclein (3).

References

- 1. www.alz.org/alzheimers-dementia/facts-figures
- 2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146–148 (1907). 3. Taschenberger G., et al. (2013) Ann Neurol. 74(1): 109-118.

Product Images

Product Citations (0)

Currently there are no citations for this product.

Reviews

There are no reviews yet.